Bristol Myers Squibb (CELG-RI) Cash from Financing Activities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Cash from Financing Activities for 18 consecutive years, with -$2.6 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 43.25% year-over-year to -$2.6 billion; the TTM figure through Jun 2026 stood at -$11.7 billion (down 40.68% YoY), while the FY2025 annual figure was -$10.3 billion, down 301.83% from the prior year.
• Cash from Financing Activities declined to -$2.6 billion in Q2 2026 per CELG-RI's latest filing, from -$1.6 billion in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $14.6 billion in Q1 2024 and bottomed at -$6.0 billion in Q4 2025.
• Historically, Cash from Financing Activities has averaged -$2.0 billion across 5 years, with a median of -$2.8 billion in 2023.
• On a YoY basis, Cash from Financing Activities climbed as much as 580.13% in 2024 and fell as far as 269.8% in 2024.
• Bristol Myers Squibb's Cash from Financing Activities stood at -$3.2 billion in 2022, then surged by 129.79% to $967.0 million in 2023, then slumped by 269.8% to -$1.6 billion in 2024, then tumbled by 267.17% to -$6.0 billion in 2025, then surged by 56.38% to -$2.6 billion in 2026.
• Business Quant data shows CELG-RI's Cash from Financing Activities at -$2.6 billion in Q2 2026, -$1.6 billion in Q1 2026, and -$6.0 billion in Q4 2025.